0
Medtech
  • Home
  • MedTech Insights
  • APAC
  • Europe ▾
    • Medical Device Manufacturing
  • Conferences
  • Newsletter
  • Subscribe
  • News
  • About Us
  • In Vitro Diagnostics
  • Medical Device Manufacturing Europe
  • Dermatology
  • APAC
  • Biomechanics
  • Nanomedicine
  • Haematology
  • Europe
  • Neurology
  • Manufacturing
  • Pediatrics
  • Chronic Care
  • Diabetes Care
  • Wound Care Technology
  • Connected Health
  • Oncology
  • Orthopedic
  • Endoscopy
  • Ophthalmics
  • Ultrasound
  • Medical Imaging
  • Dental
  • Robotics
  • Packaging and Sterilization
  • Simulation
  • Surgical
  • CardioVascular
  • In Vitro Diagnostics
  • Dental
  • Robotics
  • Packaging and Sterilization
  • Simulation
  • Surgical
  • CardioVascular
  •   MORE
      • Medical Imaging
      • Manufacturing
      • Neurology
      • Haematology
      • Nanomedicine
      • Biomechanics
      • Dermatology
      • Chronic Care
      • Diabetes Care
      • Wound Care Technology
      • Ultrasound
      • Ophthalmics
      • Endoscopy
      • Orthopedic
      • Oncology
      • Connected Health
      • Pediatrics
×

Subscribe to our mailing list for the latest articles, news, and exclusive insights

news

Subscribe to our Newsletter

Thank You for subscribing with us. We sent you an email regarding this.

loading

Subscribe Now!
Editor's Pick(1 - 4 of 8)
left
The Evolution of Talent

William Mayo, CIO, Broad Institute of MIT and Harvard

First Process, Then Tech: How HCC Coding can Close Gaps in Care

Peggy Chou, MD, MBA, Medical Director of Medical Management, Atrius Health

Disrupting The CIO Comfort Zone To Innovate And Transform How Behavioral Health Clinics Use Electronic Health Records

Wes Williams, VP & CIO, Mental Health Center of Denver

Keeping Up with the Latest Medical Trends

Joseph G Seay, Former SVP & CIO, Community Health Systems

Value Innovation in the Radiology Practice

Shannon Werb, CIO, Virtual Radiologic

IN-Vitro Diagnostics: Next Generation Point-of-Care Testing

Marcel Van Kasteel, CEO Handheld Diagnostics and CEO Biocell A/S, Philips BG Emerging Businesses

Future Trends in Telehealth

Lynn Gibson, VP / CTO, CHRISTUS Health

Let's Get Smarter About Information Management to Succeed in Population Health

Rhonda Medows, M.D., EVP of Population Health

right

The Physician You Never Knew You Had and How They Guide the Hands of Precision Oncologists

By Anthony M Magliocco, MD & Chair of Anatomic Pathology, Moffitt Cancer Center

Anthony M Magliocco, MD & Chair of Anatomic Pathology, Moffitt Cancer Center

Medical practice is changing, and its changing rapidly, particularly in the world of oncology.

We are now living in a time of “precision medicine” and “personalized Oncology” practice. The changes we are currently experiencing in the diagnosis and selection of treatment for cancer patients are truly revolutionary and are making a significant impact in ability to treat and cure cancer patients.

The initiation, development and growth of a cancer likely have a long natural history in a patient but generally the initial point of diagnosis is made at the end of a microscope by a tissue pathologist.

Pathology is often a misunderstood specialty that holds a vital role in supporting the accurate delivery of quality cancer treatment. The word “pathology” is derived from “pathos” meaning suffering, and “Logos” meaning study of—the study of suffering, or more precisely the study of disease.

Pathology is the translational science that underpins and supports the practice of clinical medicine.

Pathologists are fully qualified medical doctors who have spent 4 to 5 years specializing in the specialties of pathology after they have completed medical school. The specialties include anatomic pathology and clinical pathology. Often the pathologist will do further subspecialty training in a subspecialty such as breast pathology or hematology and some will even do additional research training in molecular diagnostics or translational research.

"Immunohistochemical stains can help determine what driver mutations are present within a cancer helping an oncologist select a specific treatment"

When a patient has a biopsy or tissue removed, it is processed in a tissue pathology laboratory and thin slices are placed on a glass slide and stained with special dyes to highlight various components within the tissue. An expert pathologist will examine the slides and determine what the medical diagnosis is. The examination will determine if a lesion is benign or malignant, will determine the grade of a malignancy-grade is a measure of biological aggressiveness. Generally grading is assigned from 1 to 3 with 3 representing the most poorly differentiated tumors and ones with the greatest risk of spread.

In addition, the pathologist will examine the margins of the surgical excision to determine if a cancer has been completely excised and will also examine adjacent tissues such as regional lymph nodes to determine if cancer has spread. Determining how far cancer has spread defines the stage of the lesion and gives information as to whether a cancer can be cured by surgical means alone.

Cancers that are localized are generally curable using a combination of surgery and possibly radiation therapy. Other tumors that have spread beyond the primary organ to adjacent organs or lymph nodes require systemic therapy which now could be endocrine therapy, chemotherapy, targeted therapy, or immunotherapy or a combination of all of these.

The pathologist has an array of advanced diagnostic tools at their disposal. They will generally use immunohistochemistry—a method that can “paint” tumors with a dye to determine if a specific protein is present.

This can be used to help determine the primary origin of a metastatic cancer when the primary is unknown. Stains such as S100 or keratin can help determine if a tumor is a melanoma or a carcinoma. A stain such as TTF1 can determine whether the tumor might be of lung origin.

Other immunohistochemical stains can help determine what driver mutations are present within a cancer helping an oncologist select a specific treatment. A good example is breast cancer. In invasive breast cancer all new cases undergo staining with antibodies against estrogen receptor, progesterone receptor, HER2, ki67 and sometimes Androgen receptor. This combination of stains can help determine if a breast cancer might be likely to respond to an anti-hormonal treatment such as tamoxifen or if an anti HER2 receptor treatment such as trastuzumab could be used.

Some cancers such as lung cancer require an extensive molecular evaluation. This examination requires performing a combination of Immunohistochemistry, fluorescent hybridization (FISH) and gene sequence analysis. This complex testing algorithm is necessary to screen for presence of targetable DNA mutations such as EGFR activating mutations, ALK, RET, ROS, NTRK translocations, or overexpression of the checkpoint control molecular PDL1.

Lung cancer with its complexity is considered one of cancers with the most advanced treatment algorithms and a plethora of treatment options. Targeted therapies have resulted in significant improvements of disease free survival. Immunotherapies have added to this with even more dramatic responses in some patients with extraordinary durable responses in some patients.

There is now an extraordinary explosion of new treatment options and therapy modalities. This is creating a crisis in clinical trials in which there are so many trials now open making it hard to fill them or to best select patients for a particular therapy.

This challenge will likely be met through the work of molecular pathologists who will create better companion diagnostics to better select patients for a specific treatment. Another tool, the liquid biopsy, which can measure mutant DNA in blood or circulating malignant cells in blood can now offer the opportunity to measure a cancer in “real time” and adjust medication on the fly—optimizing dosing to minimize toxic side effects and manage tumor control in an optimal way to avoid induction of growth escape.

While the world of precision medicine and personalized oncology continues to explode, the pathologist and molecular pathologist maintain a central role in managing the tissue and testing of samples from patients to ensure that the safest and most effective treatment options are available for use by a treating oncologist.

The role of the physician you never knew you had continues to grow!

Read Also

Value Innovation in the Radiology Practice

Value Innovation in the Radiology Practice

Shannon Werb, CIO, Virtual Radiologic
IN-Vitro Diagnostics: Next Generation Point-of-Care Testing

IN-Vitro Diagnostics: Next Generation Point-of-Care Testing

Marcel Van Kasteel, CEO Handheld Diagnostics and CEO Biocell A/S, Philips BG Emerging Businesses
Future Trends in Telehealth

Future Trends in Telehealth

Lynn Gibson, VP / CTO, CHRISTUS Health
Let's Get Smarter About Information Management to Succeed in Population Health

Let's Get Smarter About Information Management to Succeed in Population Health

Rhonda Medows, M.D., EVP of Population Health
Top 10 In-Vitro Diagnostic Technology Solution Providers - 2018

Top 10 In-Vitro Diagnostic Technology Solution Providers - 2018

In Vitro Diagnostics Special

Featured Vendors

  • Critical Diagnostics: A Novel In vitro Diagnostic Test for Heart Failure Patient Management
    Critical Diagnostics: A Novel In vitro Diagnostic Test for Heart Failure Patient Management
  • DCN Diagnostics: Pioneers of Next-Gen Lateral Flow Assays
    DCN Diagnostics: Pioneers of Next-Gen Lateral Flow Assays
  • Freudenberg Medical: Unprecedented Manufacturing Expertise
    Freudenberg Medical: Unprecedented Manufacturing Expertise
  • DiaCarta: Redefining Molecular Diagnostics through XNA
    DiaCarta: Redefining Molecular Diagnostics through XNA
Copyright © 2019 Medical Tech Outlook. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Use and Privacy Policy.
follow on linkedin follow on twitter
This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

in-vitro-diagnostics.medicaltechoutlook.com/cxoinsight/the-physician-you-never-knew-you-had-and-how-they-guide-the-hands-of-precision-oncologists-nwid-201.html?utm_source=google&utm_campaign=medicaltechoutlook_topslider